Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use

Introduction

Adverse childhood experiences (ACEs) — including abuse, neglect and other early life disruptions — are common and have far-reaching effects on health and social functioning. Earlier research links ACEs to poorer interpersonal relationships, insecure attachment, difficulties with emotion regulation and reduced resilience; these sequelae contribute to elevated risks for mental illness, premature mortality and onward intergenerational transmission of adversity. While multicomponent psychosocial interventions aimed at early childhood show modest benefits, there is no single gold-standard treatment to reverse the developmental disruptions associated with complex or prolonged childhood trauma. Against this background, renewed interest in psychedelic-assisted interventions has highlighted psilocybin as a candidate adjunct or alternative for treatment-resistant conditions that can arise from ACEs, such as post-traumatic stress disorder, anxiety and substance use disorders. The present study, led by Card Phd and colleagues, set out to investigate two questions: whether naturalistic (non-clinical) psilocybin use moderates the association between ACE burden and current psychological distress, and how acceptable psilocybin is to people with varying levels of childhood adversity as measured by their opinions and experiences with the substance. The authors framed the work as exploratory evidence about potential efficacy and acceptability, recognising that many people access psilocybin outside formal therapeutic settings.